Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Ollin Biosciences has raised $330 million in an oversubscribed Series B funding round to advance late-stage trials for its eye disease drug, OLN324. The drug, which targets leading causes of vision loss like diabetic macular edema and wet AMD, showed superior vision gains compared to Roche's Vabysmo in early studies. The funding will also move a second drug, OLN102, into human testing in 2026.

Series B funding round

• ▪Investors in the round included a16z Bio+Health, Blackstone Multi-Asset Investing, and T. Rowe Price Investment Management
• ▪The funding round was co-led by TCGX and ARCH Venture Partners
• ▪Ollin Biosciences launched in 2025 with an initial $100 million financing led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital
• ▪Ollin Biosciences, a Texas-based biotech company, raised $330 million in a Series B funding round
• ▪The Series B round was oversubscribed and was one of the largest for a biotech company in the last two years

OLN324 clinical development timeline

• ▪Ollin Biosciences plans to start the late-stage trials for OLN324 in the second half of 2026
• ▪The funding will also advance OLN102, a drug for thyroid eye disease and Graves' disease, into human testing in 2026
• ▪The new funding will support late-stage global trials for the experimental eye disease drug OLN324

Dual antibody mechanism

• ▪DME and wet AMD are leading causes of vision loss and affect millions of Americans
• ▪OLN324 is an antibody that targets two key disease signals to treat abnormal blood vessel growth and leakage in the eye
• ▪OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD)

Head-to-head trial results

• ▪The same study showed OLN324 produced greater vision gains than Vabysmo in patients with both DME and wet AMD
• ▪In an early-stage study, OLN324 showed faster and greater improvements in eye structure compared to Roche's Vabysmo

China biotech partnerships

• ▪Ollin Biosciences is developing OLN324 in collaboration with the China-based firm Innovent Biologics
• ▪The company is developing its second drug, OLN102, in partnership with the China-based firm VelaVigo